Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07213778 · ClinicalTrials.gov registry record · Phase 3
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
A Phase 3 study of Symptomatic Venous Thromboembolism (VTE), sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,000
- Enrollment target
- 10
- Study locations
NCT07213778 is a Phase 3 study of Symptomatic Venous Thromboembolism (VTE) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 2,000 participants. The trial reports 10 study locations across 8 states.
The verdict
NCT07213778, a Phase 3 study of Symptomatic Venous Thromboembolism (VTE), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,000 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study is researching an experimental drug called REGN7508 versus Acetylsalicylic Acid (ASA) (each called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery compared to acetylsalicylic acid. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG REGN7508
- DRUG Acetylsalicylic Acid (ASA)
Study Locations (10)
Florida
- Medical Research of Westchester - MPLUS Research Network - Miami
- Phoenix Clinical Research - Tamarac
Texas
- HD Research - Memorial Hermann Village - Houston
- Endeavor Clinical Trials - San Antonio
Colorado
- Sky Ridge Medical Center - Lone Tree
Kansas
- NextStage Clinical Research, St. Francis Medical Park - Wichita
Maryland
- Sinai Hospital of Baltimore, Inc. - Baltimore
New Jersey
- Holy Name Medical Center - Teaneck
Ohio
- Ohio Clinical Trials - Columbus
Washington
- Spokane Joint Replacement Center - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2025-11-24 |
| Est. Completion | 2027-07-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07213778
The ClinicalTrials.gov registry entry for NCT07213778 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Symptomatic Venous Thromboembolism (VTE) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07213778 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Florida, Texas, Colorado.
Frequently Asked Questions
What is clinical trial NCT07213778 about?
NCT07213778 is a clinical study titled "REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants". This study is researching an experimental drug called REGN7508 versus Acetylsalicylic Acid (ASA) (each called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at pr...
What is the current status of trial NCT07213778?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,000 participants. The study started on 2025-11-24. Estimated completion is 2027-07-16.
What conditions does trial NCT07213778 study?
This clinical trial studies the following conditions: Symptomatic Venous Thromboembolism (VTE).
What interventions are being tested in trial NCT07213778?
The interventions under investigation include: Placebo (DRUG), REGN7508 (DRUG), Acetylsalicylic Acid (ASA) (DRUG).
Who is sponsoring clinical trial NCT07213778?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07213778 being conducted?
This trial has 10 study locations across Colorado, Florida, Kansas, Maryland, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.